Celcuity Inc (CELC) PT Raised to $155 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Celcuity Inc (NASDAQ: CELC) to $155.00 (from $145.00) while maintaining a Buy rating.

The analyst commented: "On July 14, 2026, three days ahead of the July 17 PDUFA date, the FDA approved REVTORPYK (gedatolisib) in combination with fulvestrant +/- palbociclib, for adults with HR+/HER2- PIK3CA wild-type (WT) locally advanced or metastatic breast cancer, following progression on or after at least one line of endocrine therapy. REVTORPYK received a label generally in-line with expectations, except for the requirement of a prophylactic steroid-based, alcohol-free mouth rinse for at least the first eight weeks to manage stomatitis. Management does not expect this requirement to hinder adoption. We view this approval as thesis-confirming, marking the company’s transition to commercial-stage status. We conservatively assume gedatolisib launches in 4Q26, modestly behind management's late-3Q26 guidance, at a WAC of $26,000 per month with a 20% gross-to-net discount and apply a 15% peak penetration rate. Based on these assumptions, we raise our 12-month price target to $155 per diluted share from our prior $145."

You May Also Be Interested In

• Celcuity Inc (CELC) PT Lowered to $140 at Needham
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)